Searched for: in-biosketch:yes
person:morgag04
Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses [Letter]
Yao, Qiumei; Morgan, Gareth J; Chim, Chor Sang
Spatial and subclonal genetic heterogeneity in multiple myeloma (MM) have been demonstrated by sequencing of plasma cells from multi-focal regions, but studies of spatial epigenetic heterogeneity are scanty. Herein, promoter methylation status of genes implicated in disease progression (CDKN2A and SHP1) and marrow escape (CDH1, CD56, and CXCR4) was studied in two patients with multi-focal extramedullary relapses. Patient 1 developed simultaneous chest wall and duodenal plasmacytoma at relapse. While SHP1 and CDKN2A were hypermethylated in both plasmacytomas, CDH1 hypermethylation was detected only in the chest wall. In patient 2, SHP1 methylation was found in the extradural plasmacytoma but not bone marrow (BM) at diagnosis, and the circulating PCs but not the BM at relapse. As the clonality, based on sequence of the complementarity-determining region 3 (CDR3) of the immunoglobulin gene, was conserved in plasma cells at diagnosis and relapse, differential methylation of CDH1 in patient 1 and SHP1 in patient 2 was an illustration of spatial epigenetic heterogeneity. Furthermore, subclonal epigenetic heterogeneity was identified by the presence of subclonal SHP1 promoter methylation within the chest wall plasmacytoma of patient 1. In summary, our data showed distinct promoter methylation profile of plasma cells from multiple regions. This is the first report of spatial epigenetic heterogeneity in MM.
PMCID:6302381
PMID: 30572945
ISSN: 1868-7083
CID: 3649412
The genomic landscape of plasma cells in systemic light chain amyloidosis [Letter]
Boyle, Eileen M; Ashby, Cody; Wardell, Christopher P; Rowczenio, Dorota; Sachchithanantham, Sajitha; Wang, Yan; Johnson, Sarah K; Bauer, Michael A; Weinhold, Niels; Kaiser, Martin F; Johnson, David C; Jones, John R; Pawlyn, Charlotte; Proszek, Paula; Schinke, Carolina; Facon, Thierry; Dumontet, Charles; Davies, Faith E; Morgan, Gareth J; Walker, Brian A; Wechalekar, Ashutosh D
PMID: 30446495
ISSN: 1528-0020
CID: 3649392
Subclonal TP53 copy number is associated with prognosis in multiple myeloma
Shah, Vallari; Johnson, David C; Sherborne, Amy L; Ellis, Sidra; Aldridge, Frances M; Howard-Reeves, Julie; Begum, Farzana; Price, Amy; Kendall, Jack; Chiecchio, Laura; Savola, Suvi; Jenner, Matthew W; Drayson, Mark T; Owen, Roger G; Gregory, Walter M; Morgan, Gareth J; Davies, Faith E; Houlston, Richard S; Cook, Gordon; Cairns, David A; Jackson, Graham; Kaiser, Martin F
Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 newly diagnosed Myeloma XI trial patients with multiplex ligation-dependent probe amplification (MLPA). Subclonal TP53 deletions were independently associated with shorter overall survival, with a hazard ratio of 1.8 (95% confidence interval, 1.2-2.8; P = .01). Clonal, but not subclonal, TP53 deletions were associated with clinical markers of advanced disease, specifically lower platelet counts (P < .001) and increased lactate dehydrogenase (P < .001), as well as a higher frequency of features indicative of genomic instability, del(13q) (P = .002) or del(1p) (P = .006). Biallelic TP53 loss-of-function by mutation and deletion was rare (2.4%) and associated with advanced disease. We present a framework for identifying subclonal TP53 deletions by MLPA, to improve patient stratification in MM and tailor therapy, enabling management strategies.
PMID: 30373884
ISSN: 1528-0020
CID: 3649382
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis
Bødker, Julie Støve; Brøndum, Rasmus Froberg; Schmitz, Alexander; Schönherz, Anna Amanda; Jespersen, Ditte Starberg; Sønderkær, Mads; Vesteghem, Charles; Due, Hanne; Nørgaard, Caroline Holm; Perez-Andres, Martin; Samur, Mehmet Kemal; Davies, Faith; Walker, Brian; Pawlyn, Charlotte; Kaiser, Martin; Johnson, David; Bertsch, Uta; Broyl, Annemiek; van Duin, Mark; Shah, Rajen; Johansen, Preben; Nørgaard, Martin Agge; Samworth, Richard J; Sonneveld, Pieter; Goldschmidt, Hartmut; Morgan, Gareth J; Orfao, Alberto; Munshi, Nikhil; Johnson, Hans Erik; El-Galaly, Tarec; Dybkær, Karen; Bøgsted, Martin
Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and optimize therapy. Here we propose a new subtyping of myeloma plasma cells (PCs) from diagnostic samples, assigned by normal B-cell subset associated gene signatures (BAGS). For this purpose, we combined fluorescence-activated cell sorting and gene expression profiles from normal bone marrow (BM) Pre-BI, Pre-BII, immature, naïve, memory, and PC subsets to generate BAGS for assignment of normal BM subtypes in diagnostic samples. The impact of the subtypes was analyzed in 8 available data sets from 1772 patients' myeloma PC samples. The resulting tumor assignments in available clinical data sets exhibited similar BAGS subtype frequencies in 4 cohorts from de novo MM patients across 1296 individual cases. The BAGS subtypes were significantly associated with progression-free and overall survival in a meta-analysis of 916 patients from 3 prospective clinical trials. The major impact was observed within the Pre-BII and memory subtypes, which had a significantly inferior prognosis compared with other subtypes. A multiple Cox proportional hazard analysis documented that BAGS subtypes added significant, independent prognostic information to the translocations and cyclin D classification. BAGS subtype analysis of patient cases identified transcriptional differences, including a number of differentially spliced genes. We identified subtype differences in myeloma at diagnosis, with prognostic impact and predictive potential, supporting an acquired B-cell trait and phenotypic plasticity as a pathogenetic hallmark of MM.
PMCID:6156884
PMID: 30254104
ISSN: 2473-9537
CID: 3649372
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis
Gay, Francesca; Jackson, Graham; Rosiñol, Laura; Holstein, Sarah A; Moreau, Philippe; Spada, Stefano; Davies, Faith; Lahuerta, Juan José; Leleu, Xavier; Bringhen, Sara; Evangelista, Andrea; Hulin, Cyrille; Panzani, Ugo; Cairns, David A; Di Raimondo, Francesco; Macro, Margaret; Liberati, Anna Marina; Pawlyn, Charlotte; Offidani, Massimo; Spencer, Andrew; Hájek, Roman; Terpos, Evangelos; Morgan, Gareth J; Bladé, Joan; Sonneveld, Pieter; San-Miguel, Jesús; McCarthy, Philip L; Ludwig, Heinz; Boccadoro, Mario; Mateos, Maria-Victoria; Attal, Michel
Importance/UNASSIGNED:Several trials demonstrated the impact of novel agent-based maintenance in newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating the superiority of one regimen over the other, owing to the lack of direct/indirect comparisons. Objective/UNASSIGNED:To analyze and compare the effectiveness of different maintenance regimens in NDMM via a network meta-analysis. Data Sources/UNASSIGNED:We performed 2 independent searches in PubMed and Cochrane databases, and then we identified all the records registered after 1999 and on or before November 20, 2017. Study Selection/UNASSIGNED:By blinded review, we identified prospective phase 3 randomized trials evaluating novel agent-based maintenance in patients with NDMM; the included studies compared at least 2 maintenance approaches; comparators included placebo and no maintenance. From 364 screened records, 11 studies were included. Data Extraction and Synthesis/UNASSIGNED:We followed (independent extraction) the guidelines provided by the PRISMA Report and the EQUATOR Network. The evidence was synthesized using a network meta-analysis (NMA). To allow comparison of all treatments, no maintenance was selected as common comparator and the effect of placebo was assumed to be the same as no treatment. The best option was identified by a Bayesian consistency model based on hazard ratio (HR), 95% credible interval (CrI), probability of being the best treatment (PbBT), and median ranking distribution (MedR). Main Outcomes and Measures/UNASSIGNED:Outcomes of interest were progression-free survival (PFS) and overall survival (OS). Results/UNASSIGNED:Eleven trials and 8 treatments including a total of 5073 participants were included. By PFS analysis, lenalidomide-based regimens (lenalidomide-prednisone, lenalidomide alone) were identified as the most effective options (HR, 0.39 [95% CrI, 0.28-0.53] and 0.47 [95% CrI, 0.39-0.55], respectively; MedR, 1 and 2; overall PbBT, 74%). Four treatments (thalidomide-interferon, thalidomide-bortezomib, bortezomib-prednisone, thalidomide alone) showed an HR in favor of maintenance. By OS analysis, lenalidomide alone was identified as the best option (HR, 0.76; 95% CrI, 0.51-1.16; MedR, 2; PbBT, 38%), followed by bortezomib-thalidomide and bortezomib-prednisone. Similar features were noticed in the restricted network including transplant trials, in the sensitivity analysis, and in most of the prognostic subgroups. Conclusions and Relevance/UNASSIGNED:Based on PFS and OS results of this NMA, lenalidomide maintenance appears to be the best treatment option, by synthesizing the available evidence of novel agent-based maintenance in the past 20 years.
PMCID:6233774
PMID: 30098165
ISSN: 2374-2445
CID: 3649352
Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
Yadav, Punit; Cockwell, Paul; Cook, Mark; Pinney, Jennifer; Giles, Hannah; Aung, Yu Sandar; Cairns, David; Owen, Roger G; Davies, Faith E; Jackson, Graham H; Child, J Anthony; Morgan, Gareth J; Drayson, Mark T
BACKGROUND:Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor survival. This study reports the associations between renal function and disease characteristics including serum free light chain (FLC) level at diagnosis in patients with MM. METHODS:Using data from the Medical Research Council Myeloma IX trial, a multicentre, randomized, open-label, phase III and factorial-design trial, we assessed the relationships between renal function, demographic, and disease characteristics, including serum FLC levels, in 1595 newly diagnosed MM patients. Multivariable linear regression was utilised to identify factors that were associated with renal function at diagnosis. A receiver operating characteristic curve (ROC) was used to identify the optimal threshold for serum FLC level at diagnosis to predict severe RI. RESULTS:(severe RI). In a multivariable analysis, factors independently and negatively associated with eGFR at diagnosis were: higher serum FLC level, female gender, and older age. Elevated serum FLC level at diagnosis, irrespective of the paraprotein type, was strongly associated with severe RI. Receiver operating characteristic curve analysis showed a serum FLC level of > 800 mg/L as the optimal cut-off associated with severe RI (area under curve 0.86, 95% confidence interval 0.77-0.84). CONCLUSION/CONCLUSIONS:There was a strong relationship between higher serum FLC levels at diagnosis and the severity of RI that was irrespective of the paraprotein type. We report an increased risk of severe RI in patients presenting with serum FLC levels above 800 mg/L at diagnosis.
PMCID:6048743
PMID: 30012107
ISSN: 1471-2369
CID: 3649332
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
Royle, Kara-Louise; Gregory, Walter M; Cairns, David A; Bell, Sue E; Cook, Gordon; Owen, Roger G; Drayson, Mark T; Davies, Faith E; Jackson, Graham H; Morgan, Gareth J; Child, J Anthony
In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) followed by autologous stem cell transplant (ASCT) in the intensive pathway; attenuated CTD or melphalan and prednisolone (MP) in the non-intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires, QLQ-C30 and QLQ-MY24, were administered at baseline, 3, 6 and 12Â months and annually thereafter, enabling the effect of sequential treatment on patient-reported health-related QoL (HR-QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12Â months that were compared using linear models. The intensive pathway showed significant differences in favour of CTD for Fatigue at 3Â months and Physical Functioning at 12Â months. The non-intensive pathway and maintenance phase reported significant differences at 3Â months; Pain (improved with attenuated CTD) and Global Health status/Quality of Life (improved with observation). The improved outcomes in MRC Myeloma IX were accompanied by some beneficial and few detrimental effects on HR-QoL.
PMCID:6175065
PMID: 29984830
ISSN: 1365-2141
CID: 3649322
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Pawlyn, Charlotte; Loehr, Andrea; Ashby, Cody; Tytarenko, Ruslana; Deshpande, Shayu; Sun, James; Fedorchak, Kyle; Mughal, Tariq; Davies, Faith E; Walker, Brian A; Morgan, Gareth J
PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Multiple myeloma (MM) is a genetically unstable tumor and we hypothesized that HRD-related LOH (HRD-LOH) could be detected in patient samples, supporting a potential role for PARP inhibition in MM. Using results from targeted next-generation sequencing studies (FoundationOne® Heme), we analyzed HRD-LOH in patients at all disease stages (MGUS (n = 7), smoldering MM (SMM, n = 30), newly diagnosed MM (NDMM, n = 71), treated MM (TRMM, n = 64), and relapsed MM (RLMM, n = 234)) using an algorithm to identify HRD-LOH segments. We demonstrated HRD-LOH in MM samples, increasing as disease progresses. The extent of genomic HRD-LOH correlated with high-risk disease markers. Outcome of RLMM patients, the biggest clinical group, was analyzed and patients with HRD-LOH above the third quartile (≥5% HRD-LOH) had significantly worse progression-free and overall survival than those with lower levels (p < 0.001). Mutations in key homologous recombination genes account for some, but not all, of the cases with an excess of HRD-LOH. These data support the further evaluation of PARP inhibitors in MM patients, particularly in the relapsed setting with a high unmet need for new treatments.
PMCID:6035152
PMID: 29467487
ISSN: 1476-5551
CID: 3649182
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Schinke, Carolina; Qu, Pingping; Mehdi, Syed J; Hoering, Antje; Epstein, Joshua; Johnson, Sarah K; van Rhee, Frits; Zangari, Maurizio; Thanendrarajan, Sharmilan; Barlogie, Bart; Davies, Faith E; Yaccoby, Shmuel; Morgan, Gareth J
Purpose: Mesenchymal stem cells (MSC) are an essential component of the bone marrow microenvironment and have shown to support cancer evolution in multiple myeloma. Despite the increasing evidence that multiple myeloma MSCs differ from their healthy counterparts, little knowledge exists as to whether MSCs independently influence disease outcome. The aim of this study was to determine the importance of MSCs in disease progression and outcome in multiple myeloma.Experimental Design: To determine the impact of MSCs on multiple myeloma outcome in an in vivo system, we first identified genes from cultured MSCs that were specific to MSC expression and were not or minimally expressed in plasma cells (PC) or other cells present in bone marrow aspirates. We then applied this MSC gene signature to whole bone marrow biopsies of multiple myeloma patients compared with healthy controls and determined MSC expression scores specific to multiple myeloma and predictive of outcome.Results: We show that multiple myeloma MSC gene expression signatures can differentiate multiple myeloma from monoclonal gammopathy and smoldering multiple myeloma (SMM) as well as from healthy controls and treated multiple myeloma patients who have achieved a complete remission. We identified a prognostic gene score based on three MSC specific genes, COL4A1, NPR3 and ITGBL1, that was able to predict progression-free survival in multiple myeloma patients and progression into multiple myeloma from SMM.Conclusions: Our findings show that progression of multiple myeloma and of SMM into multiple myeloma does not rely solely on intrinsic PC factors, but is independently affected by the biology of the surrounding microenvironment. Clin Cancer Res; 24(12); 2913-9. ©2018 AACR.
PMID: 29563136
ISSN: 1078-0432
CID: 3649222
Hybrid Strategy for High-Risk Neonates with Interrupted Aortic Arch: A Can Well Worth Kicking?
Kapravelou, Eva; Anderson, David; Morgan, Gareth J
The use of hybrid techniques to avoid neonatal cardiopulmonary bypass in high-risk individuals is well reported in the setting of hypoplastic left heart syndrome. We describe the use of that technique as a bridging procedure in high-risk neonates with an interrupted aortic arch. We report three cases where hybrid branch pulmonary artery banding and ductal stent implantation has been successfully used to defer complete repair, allowing recovery, maturity, and weight gain. This strategy may be considered for patients deemed at high risk for primary neonatal repair.
PMCID:5825225
PMID: 29483768
ISSN: 1061-1711
CID: 3649212